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ABSTRACT
The androgen receptor (AR) is a transcription factor involved in prostate cell 
growth, homeostasis and transformation regulated by post-translational modifications, 
including ubiquitination. We have recently reported that AR is deubiquitinated and 
stabilised by Usp12 resulting in increased transcriptional activity. In this study 
we have investigated the relationship between Usp12, PHLPP and PHLPPL tumour 
suppressors in the regulation of AR transcriptional activity in prostate cancer 
(PC). PHLPP and PHLPPL are pro-apoptotic phosphatases that dephosphorylate 
and subsequently deactivate Akt. Phosphorylated Akt is reported to deactivate AR 
in PC by phosphorylation at Ser213 and Ser791 leading to ligand dissociation and 
AR degradation. In contrast, PHLPP- and PHLPPL-mediated dephosphorylation and 
inactivation of Akt elevates the levels of active AR. In this report we demonstrate 
that Usp12, in complex with Uaf-1 and WDR20, directly deubiquitinates and stabilises 
the Akt phosphatases PHLPP and PHLPPL resulting in decreased levels of active pAkt. 
Decreased pAkt in turn down-regulates AR Ser213 phosphorylation resulting in 
enhanced receptor stability and transcriptional activity. Additionally, we observe that 
depleting Usp12 sensitises PC cells to therapies aimed at Akt inhibition irrespectively 
of their sensitivity to androgen ablation therapy. We propose that Usp12 inhibition 
could offer a therapeutic alternative for castration resistant prostate cancer.
INTRODUCTION
Prostate cancer (PC) is the most common non-
cutaneous cancer affecting Western males, accounting 
for over a million cases diagnosed worldwide in 2012 
according to WHO. Androgen receptor (AR) signalling 
plays a major role in prostate cancer development. 
The AR is a transcription factor that belongs to the 
nuclear hormone receptor family and regulates the 
expression of genes involved in prostate proliferation 
and apoptosis [1]. Deregulated AR activity disrupts the 
balance between proliferation and apoptosis leading to 
cellular transformation; and hence the receptor signalling 
cascade remains the primary therapeutic target for PC 
treatment [2]. After a preliminary stage of hormone-
sensitive disease that is treated by androgen-deprivation 
therapy and agents directly inactivating the AR, patients 
progress to castrate resistant prostate cancer (CRPC) for 
which there is no curative treatment available with an 
extremely poor prognosis. Importantly, the AR remains a 
crucial driver of CRPC, as evidenced by elevated levels of 
the AR-regulated gene PSA and AR gene amplification and 
mutations, thus new strategies targeting the AR signalling 
cascade, both directly and indirectly, are likely to be 
efficacious in this disease state [3].
AR can be post-translationally modified by multiple 
proteins and those modifications affect its activity 
and stability. We and others have shown that the AR 
is ubiquitinated by a number of E3 ubiquitin ligases, 
including MDM2 [4], [5], CHIP [6], [7], RNF6 [8] and 
NEDD4 [9], [10] which results in proteosomal degradation 
and changes to transcriptional activity. However, very 
little is known about reversal of this modification in AR 
regulation. Usp26 was reported to deubiquitinate AR 
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resulting in receptor deactivation or MDM2 ubiquitination 
followed by AR degradation depending on cellular 
context [11]. Additionally, Usp10 was shown to bind AR 
causing an increase in its transcriptional activity [12]. 
We have recently reported that Usp12, in complex with 
Uaf-1 and WDR20, can directly bind and deubiquitinate 
the AR resulting in increased receptor stability and 
transcriptional activity [13]. As a result, depleting Usp12 
decreased PC cellular proliferation and increased cellular 
apoptosis suggesting it may be a potential target for CRPC 
therapy [13].
In this study we focused on the relationship between 
the AR and Akt pathways. The Akt pathway plays a pro-
survival and pro-proliferative role and is involved in 
prostate carcinogenesis [14], [15]. The PI3K/Akt pathway 
and AR are reported to act within a feedback loop in 
prostate cells in which Akt directly phosphorylates AR 
at S213 and S791, resulting in promotion of receptor 
degradation by driving MDM2-mediated ubiquitination 
of the AR [16], [17], [5], [18]. Additionally, AR S213 
phosphorylation represses the interaction between the AR 
and its cofactors ARA70, ARA54 and TIF-2 resulting in 
decreased transcriptional activity of the AR [16]. Similar 
effects were observed for PIM-1S phosphorylation of the 
AR at S213 [19]. In this process, S213, and not S791, 
was reported to be the primary site mediating the AR 
inhibition by Akt [16]. Importantly, clinical studies have 
demonstrated that S213 phosphorylation of AR correlated 
with pAkt and predicted decreased patient survival 
[20], [19].
The effects of Akt on AR can be opposed by the Akt 
phosphatases Pleckstrin Homology domain leucine reach 
repeat protein phosphatases, PHLPP and PHLPPL [21]. 
PHLPP dephosphorylates Akt2 and Akt3 and PHLPPL 
dephosphorylates Akt1 and Akt3 at S473 [21]. PHLPP 
and PHLPPL are reported to be lost in 30% and 50% of 
PC, respectively, highlighting their clinical importance 
[22]. PHLPP protein is regulated by ubiquitination by 
the SCF-b-TrcP complex leading to its proteosomal 
degradation [23]. Interestingly, this can be reversed by 
two closely-related Usp12 family members, Usp46 in 
colon cancer [24] and Usp1 in lung cancer [25] which both 
deubiquitinate and stabilise PHLPP. Additionally, Usp12 
was predicted to interact with both of these phosphatases 
and a more recent report confirmed the interaction between 
Usp12 and PHLPP in colorectal cells [26].
Here we report that Usp12, in complex with 
Uaf-1 and WDR20, interacts with PHLPP and PHLPPL 
in PC cells resulting in their deubiquitination and 
protein stabilisation. Consequently, Usp12 decreases 
the levels of active phospho-Akt (pAkt). As a result 
Usp12 regulates the cross-talk between the Akt and AR 
pathways. As such, overexpressing Usp12 inhibits AR 
S213 phosphorylation resulting in increased AR stability 
and transcriptional activity. Additionally, depleting 
Usp12 sensitises PC cells to Akt inhibition irrespectively 
of their AR status. Therefore, we have deciphered 
a novel regulatory pathway of the AR that may be 
translationally-relevant in CRPC that is characterised by 
elevated pAkt.
RESULTS
The Usp12 complex interacts with PHLPP 
and PHLPPL
A previous proteomics study predicted PHLPP and 
PHLPPL as potential interacting partners of Usp12 [27]. 
To establish if this was the case in PC cell lines, we firstly 
investigated potential Usp12-PHLPP/L interactions in 
androgen-dependent LNCaP cells by immunoprecipitation. 
In agreement with the previous study, we found that 
both PHLPP (Figure 1A) and PHLPPL (Figure 1B) 
interacted with Usp12. Additionally, we also show 
that two components of the Usp12 complex Uaf-1 and 
WDR20 [28], [29] interacted with both phosphatase 
enzymes (Figure 1A/B). To assess the stoichiometry of 
the complex, we overexpressed PHLPP and PHLPPL 
together with the components of the Usp12 multimer and 
assessed by immunoprecipitation the minimal complex 
structure required for the interaction. Both Usp12 and 
WDR20 alone were able to interact with both PHLPP 
(Figure 1C) and PHLPPL (Figure 1D). Interaction between 
Uaf-1 and PHLPP or PHLPPL appears to be indirect, as 
in both cases, WDR20 was required for this association 
(Figure 1C-D). This is in agreement with previous reports 
demonstrating that WDR20 is the bridging component in 
the Usp12 complex required for the appropriate display 
of Uaf-1 and Usp12. We further confirmed the lack of 
direct interaction between Uaf-1 and PHLPP or PHLPPL 
using immunoprecipitation in the reverse direction 
(Figure 1E-F). It is possible that binding of PHLPP or 
PHLPPL to Uaf-1 requires a conformational change that 
is facilitated by Uaf-1 becoming part of the WDR20 and 
Usp12 complex.
Usp12 deubiquitinates and stabilises PHLPP and 
PHLPPL and controls Akt activation status
PHLPP protein stability was previously shown to be 
regulated by ubiquitination by SCF-b-TrcP complex [23], 
similar regulation probably occurs for PHLPPL. As Usp12 
is a deubiquitinating enzyme we hypothesised that PHLPP 
and PHLPPL could be potential targets for ubiquitination 
reversal by Usp12. To assess this, we overexpressed 
ubiquitin, Usp12 and either PHLPP or PHLPPL in 
COS-7 cells prior to treatment with the proteosomal 
inhibitor MG-132, to maximise the levels of 
ubiquitinated phosphatase enzymes, followed by lysis 
under denaturing conditions that permits exclusive 
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detection of ubiquitinated PHLPP or PHLPPL without 
contamination by interacting proteins. Lysates, were 
immunoprecipitated with anti-PHLPP or PHLPPL 
antibodies and the levels of ubiquitinated PHLPP and 
PHLPPL visualised by immunoblotting using an anti-
ubiquitin antibody. In agreement with previous reports, 
both phosphatases were ubiquitinated in cells (Figure 2A, 
lanes 2 and 4). Importantly, overexpression of Usp12 
deubiquitinated both PHLPP and PHLPPL (Figure 2A, 
lanes 1 and 3) and this elevated the steady-state levels of 
the enzymes, while overexpression of an enzymatically 
inactive Usp12C48A mutant failed to elevate PHLPP and 
PHLPPL levels suggesting the importance of Usp12 
enzymatic activity for phosphatase regulation (Figure 2B 
and Figure 2C). Similarly, when we silenced Usp12, or 
its interacting partners Uaf-1 and WDR20, levels of 
PHLPP and PHLPPL were decreased in LNCaP PC cells 
(Figure 2D).
Figure 1: Usp12 in complex with Uaf-1 and WDR20 interacts with PHLPP and PHLPPL. (A-B) LNCaP cells were 
harvested and lysates immunoprecipitated for either endogenous PHLPP (A), PHLPPL (B) or non-specific IgG. (C-D) COS-7 cells 
were transfected with plasmids as indicated. 72h post transfection cells were harvested and lysates were immunoprecipitated (IP) with 
PHLPP (C) or PHLPPL (D) antibody followed by immunoblotting. (E-F) COS-7 cells were transfected with plasmids as indicated. 
72h post transfection cells were harvested and lysates were immunoprecipitated (IP) with Flag antibody for Uaf-1-Flag followed by 
immunoblotting.
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As PHLPP and PHLPPL control the levels of active 
pAkt, we evaluated the effects of depleting components 
of the Usp12 complex on Akt status. Knockdown of 
Usp12, or its complex members Uaf-1 and WDR20, 
increased Akt phosphorylation without any change to the 
total Akt protein in PC cells (Figure 2E). Increased Akt 
activity was further confirmed by the increase in 4E-BP1 
and ERK1/2 Akt target proteins phosphorylation levels 
(Figure 2E). Our results confirm that Usp12 controls 
Akt phosphorylation in PC cells by deubiquitinating 
and stabilising two Akt phosphatases PHLPP and 
PHLPPL.
Usp12 regulates AR phosphorylation by 
controlling pAkt levels
Akt has been previously reported to phosphorylate 
AR at S213 and S791 [17]. We have recently shown that 
Figure 2: Usp12 deubiquitinates and stabilises PHLPP and PHLPPL and as a result controls the levels of pAkt. 
(A) COS-7 cells were transfected with p-HA-PHLPP, p-HA-PHLPPL, p-His-Ub and p-Flag-Usp12 plasmids as indicated. 72h post 
transfection cells were treated with MG-132 and harvested 16h later. Lysates were denatured and subsequently immunoprecipitated (IP) 
with HA antibody (PHLPP and PHLPPL) followed by immunoblotting. (B-C) COS-7 cells were transfected with PHLPP (B) and PHLPPL 
(C) and with increasing amounts (75-300ng) of WT or C48A mutant Usp12 for 72h. Reactions were balanced with empty pCMV vector. 
Cells were lysed followed by immunoblotting. (D-E) LNCaP cells were treated with siRNA as indicated, at 96h cells were lysed followed 
by immunoblotting.
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Usp12 has a direct effect on AR by deubiquitinating and 
stabilising the AR [13]. To assess if Usp12 additionally 
controls AR phosphorylation and activity by regulating 
pAkt levels, we overexpressed AR and Usp12 in the PC3 
prostate cancer cell line and assessed the phosphorylation 
status of the receptor. AR S213 phosphorylation was 
reduced in response to Usp12 overexpression despite 
total AR protein levels remaining stable (Figure 3A, 
compare lanes 4 and 6). To confirm that changes in AR 
phosphorylation were caused by pAkt we analysed the 
levels of pS213AR after treatment with Akt inhibitor MK-
2206. Akt inhibition abrogated S213 phosphorylation of 
AR and decreased the ability of Usp12 to stabilise AR 
protein levels (Figure 3A). Additionally, we assessed the 
levels of AR phosphorylation upon Usp12 inhibition, 
to this end we incubated PC3 cells in the presence of 
GW7647, a Usp1 and Usp12 inhibitor (unpublished data, 
Harle et al.). GW7647 caused an increase in pAkt levels 
and as a result increased AR S213 phosphorylation. We 
further confirmed this result by repeating this experiment 
in COS-7 cells where Usp12 had the same effect 
(Figure 3B). To assess if Usp12 regulates endogenous AR 
S213 modification, the receptor was immunoprecipitated 
from LNCaP cells depleted of Usp12 and phosphorylation 
assessed by immunoblotting. In agreement with the above 
result, knockdown of Usp12 in LNCaP cells increased both 
AR S213 phosphorylation and AR turnover (Figure 3C). 
Our data demonstrates that Usp12 increases the levels 
Figure 3: Usp12 controls the levels of AR Serine 213 phosphorylation by Akt. (A) PC3 cells were transfected with AR 
and Usp12 plasmids as indicated. 48 hours post transfection cells were treated with 1µM MK-2206 or 1µM GW7647 for a further 24h. 72h 
post transfection cells were harvested and immunoblotted. (B) COS-7 cells were transfected with AR and Usp12 plasmids as indicated, 48h 
post transfection cells were treated with 1µM MK-2206 for a further 24h. 72h post transfection cells were harvested and immunoblotted. 
(C) LNCaP cells were treated with siRNA as indicated for 96h, following silencing cells were harvested and lysates were immunoprecipitated 
(IP) with AR antibody followed by immunoblotting. (D) Left panel, phosphorylated Akt (pAkt) phosphorylates AR resulting in ligand 
disassociation and increased AR degradation. This can be inhibited by PTEN. Additionally, PHLPP and PHLPPL chaperoned by FKBP5 
dephosphorylate pAkt resulting in its inactivation (Akt). When Akt is inactive, AR remains bound to its ligand and translocates to the 
nucleus where it acts as a transcription factor for multiple androgen regulated genes, including FKBP5. This pathway is controlled by 
ubiquitination of both PHLPP and PHLPPL and AR leading to their proteasomal degradation. Right panel, predicted role of Usp12 as a 
regulator of the Akt pathway and AR interaction. Usp12 deubiquitinates AR rescuing it from proteosomal degradation. Additionally, Usp12 
deubiquitinates PHLPP and PHLPPL resulting in decreased Akt activity, inhibition of AR Ser213 and Ser791 phosphorylation by Akt and 
enhanced AR stability.
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of PHLPP and PHLPPL that in turn decreases the active 
pAkt pool and inhibits AR S213 phosphorylation by Akt. 
This further explains our previous observation that Usp12 
silencing has both cytotoxic and anti-proliferative effects 
on PCa cells [13]. We hypothesise that Usp12 controls the 
levels of AR both directly by deubiquitinating AR itself 
and indirectly by inhibiting Akt activity and AR S213 
phosphorylation via stabilisation of PHLPP/L and as such 
Usp12 is a guardian of the interaction between the Akt and 
AR pathways (Figure 3D).
S213 of AR is required for transcriptional  
co-activation by Usp12 and Uaf-1
AR S213/S791phosphorylation by Akt was reported 
to decrease AR-mediated transcription by inhibiting 
co-activator interaction and promoting receptor 
degradation [17]. To confirm these results, we created 
AR mutants deficient in these phosphorylation sites by 
substituting both serines with alanine. We then assessed 
their transcriptional activity in the absence and presence 
of androgen stimulation. In steroid-depleted conditions, 
only the double S213A S791A mutant had significantly 
increased transcriptional activity compared to wild type 
AR (Figure 4A). However, in the presence of DHT all 
mutants of AR had significantly increased transcriptional 
activity (Figure 4A). Interestingly, in agreement 
with previous reports, S213A substitution enhanced 
transcriptional activity of AR to a greater extent than 
that of S791A, with the most significant effect observed 
for the double mutant (Figure 4A). To ensure that this 
change in AR activity is a result of phosphorylation by 
Akt we treated cells with an Akt inhibitor. Akt inhibition 
increased transcriptional activity of wild type and both 
S213A and S791A mutants of AR but not of the double 
S213A; S791A mutant (Figure 4A). Our results confirm 
that phosphorylation of AR by Akt at both S213 and S791 
decreases AR transcriptional activity.
We have recently reported that Usp12, in 
combination with Uaf-1, can increase the transcriptional 
activity of AR [13], and hence we wanted to analyse the 
importance of Akt phosphorylation sites in this process. 
Although both AR
S213A
 and AR
S213A/S791A
 demonstrated 
elevated transcriptional activity compared to wild-type, 
both were refractory to ectopically-expressed Usp12 
and Uaf-1 (Figure 4B). To investigate if this was caused 
by the lack of interaction between AR and Usp12 in the 
absence of the specific serine residues, we overexpressed 
Usp12 alongside wild-type and mutant ARs followed by 
immunoprecipitation. Usp12 was capable of interacting 
with both AR
S213A
 and AR
S213A/S791A
 with comparable 
efficiency to wild-type confirming that these sites are 
not required for this interaction (Figure 4C). This data 
suggests that AR co-activation by Usp12 and Uaf-1 is 
largely driven through negating AR phosphorylation by 
Akt inactivation.
Figure 4: AR Ser213 is required for the upregulation of transcriptional activity by Usp12 and Uaf-1. (A-B) HEK293T 
cells were transfected with pARE3-luc, pCMV-b-gal, pFlag-AR (A) and pARE3-luc, pCMV-b-gal, pFlag-AR, pFlag-Usp12, and 
pFlag-Uaf-1 (B) as indicated and cultured for 72h in steroid depleted conditions followed by addition of 10 nM DHT for 24h where 
indicated. Results are represented as luciferase counts per second normalised to b-galactosidase activity. Data are a mean +/- SEM of three 
independent experiments normalised to WT AR alone, statistical significance was analysed with t-test. 
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Depleting Usp12 sensitises PC cells to 
Akt inhibition
Our data confirms that Usp12 controls the levels 
of pAkt in PC cells by deubiquitinating and stabilising 
two Akt phosphatases PHLPP and PHLPPL. Depleting 
Usp12 results in increased pAkt and as such predisposes 
Akt to be a major driver of cellular proliferation under those 
conditions. To assess the impact of Usp12 depletion on Akt 
inhibition we used three different compounds, GDC-0941 
which is a PI3K inhibitor acting upstream of Akt and two 
direct Akt inhibitors MK-2206 and Perifosine. We analysed 
cellular proliferation in LNCaP (castration sensitive), 
LNCaP-AI (castration resistant) and PC3 (AR negative) PC 
cells using two separate assays. We report that depleting 
Usp12 significantly sensitised PC cells to Akt inhibition 
irrespectively of their castration sensitivity or AR status 
(Figure 5A-C and 6A-C).
DISCUSSION
Regulation of AR protein levels and activity by 
post-translational modifications is known to regulate 
both normal and malignant prostate cells. Alterations in 
this control system have been reported to affect disease 
outcome and survival prognosis [30]. This is demonstrated 
by the continued importance of the AR in CRPC where it 
still remains the main focus of therapeutic strategies [2]. 
Therapies aimed at the AR invariably fail as a result of AR 
becoming promiscuous through mutations, acquiring the 
ability to become activated by a variety of steroid based 
ligands and anti-androgens, and AR amplification [2]. 
Therefore, a possible strategy for new CRPC therapeutics 
is to focus on upstream co-regulators of the AR as these 
directly control transcriptional potency of the receptor. PC 
development and progression is affected by Akt signalling 
which promotes cellular growth and proliferation, and acts 
in a feedback loop with the AR [14]. Akt activity is also 
regulated by post-translational modifications with tight 
regulation being imposed by phosphatases including PTEN, 
PHLPP and PHLPPL [31].
Usp12 was previously predicted to interact with 
PHLPPs using proteomics tools [27], as a result the 
interplay between Usp12 and PHLPPs was investigated. 
We demonstrated that Usp12, and two Usp12-interacting 
proteins, Uaf-1 and WDR20 [28], [29], form a complex with 
PHLPP and PHLPPL. Further analysis using denaturing 
immunoprecipitation experiments revealed that Usp12 can 
Figure 4: (C) COS-7 cells were transfected with WT, S213A, S791A and double S213A and S791A mutant AR alongside 
Usp12 as indicated. 72h post transfection cells were harvested and lysates were immunoprecipitated (IP) with AR antibody 
followed by immunoblotting.
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Figure 5: Usp12 depletion sensitises PC cells to Akt inhibition irrespectively of their castration sensitivity and AR 
status indicated by decreased cellular occupation of the wells. (A-C) LNCaP, LNCaP-AI and PC3 cells respectively were treated 
with siRNA and compounds as indicated. Cells were grown in their respective full media (FM); LNCaP and PC3 cells were grown in steroid 
containing media and LNCaP-AI were grown in steroid depleted media. Cellular occupation of the wells was measured every 4h using the 
IncuCyte system. Data are a mean of three independent experiments.
also deubiquitinate and stabilise both PHLPP and PHLPPL. 
This is the first report detailing the regulation of PHLPPL 
by deubiquitination, as PHLPPL dephosphorylates distinct 
isoforms of Akt than PHLPP it is crucial to understand 
the post-translational regulation of this phosphatase. 
Additionally, we found that in the presence of Usp12, AR 
S213 phosphorylation, an Akt target site, was decreased 
suggesting that Akt activity was reduced. This was confirmed 
in PC cells where Usp12 depletion caused an increase in both 
pAkt and phosphorylated AR S213 levels.
We demonstrate that Usp12 plays a crucial role 
in PC by firstly, directly deubiquitinating the AR and 
rescuing it from proteosomal degradation resulting in 
increased AR protein and activity [13]. Secondly, Usp12 
deubiquitinates and stabilises PHLPP and PHLPPL proteins 
which enhances dephosphorylation and deactivation of 
Akt. Consequently, pAkt levels are decreased inhibiting 
subsequent S213AR phosphorylation and thereby increasing 
the pool of transcriptionally active AR which is the main 
driver of PC tumourigenesis. Our results indicate that direct 
activity of Usp12 resulting in AR deubiquitination might be 
more important to maintain AR protein levels [13] where 
indirect action via Akt controls AR transcriptional activity 
(Figure 4B). This supports previous reports that AR S213 
phosphorylation by Akt causes dissociation of AR from its 
co-factors resulting in decreased transcriptional activity [16]. 
We hypothesise that Usp12 might be a crucial regulator of 
the balance between cell survival and apoptosis by acting as 
a master regulator of the known feedback loop between AR 
and the PI3K/Akt pathway.
It is not uncommon for the same DUB to regulate 
AR in both a direct and indirect manner. Usp10, another 
DUB reported to target AR, was also shown to enhance AR 
activity by combining both direct and indirect activity. Usp10 
can bind to AR and positively regulate its transcriptional 
activity [12] however, it also regulates AR indirectly via 
deubiquitination of H2A.Z causing the same effect [32]. 
Our study adds to this model highlighting the complexity in 
regulation of cellular pathways.
Similarly to Akt, PIM-1S was demonstrated to 
phosphorylate AR at S213 resulting in AR degradation and 
inhibition of its transcriptional activity [19]. PIM-1S works 
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within a feedback loop with PIM-1L which has an opposite 
effect [19]. Further investigation of the relationship 
between Usp12 and PIM-1S and PIM-1L might uncover 
an additional layer of AR regulation by Usp12. Our results 
suggest that Usp12 might be a valid drug target. We found 
that depleting Usp12 protein resulted in the sensitisation 
of prostate cancer cells to Akt inhibition irrespectively of 
their androgen sensitivity and AR status. Interestingly, 
inhibition of Usp1, a close homologue of Usp12 has 
been shown to have promising results in lung cancer 
systems which was achieved by inhibiting the Usp1-Uaf-1 
complex [33], [34]. The same approach could potentially 
be employed to inhibit Usp12.
MATERIALS AND METHODS
Antibodies, plasmids and reagents
The following antibodies were used during 
this project anti-Flag, anti-Uaf-1, anti-Usp12, anti-
a-tubulin and anti-PHLPP provided by Sigma. Anti-
AR (N20 clone), anti-HA (Y11 clone), anti-WDR20, 
Figure 6: Usp12 depletion is an independent sensitiser to therapies aimed at Akt. (A-C) LNCaP, LNCaP-AI and PC3 
cells respectively were treated with siRNA and compounds as indicated. Cells were grown in their respective full media (FM); LNCaP 
and PC3 cells were grown in steroid containing media and LNCaP-AI were grown in steroid depleted media. Cellular proliferation was 
measured after 96h by cell counting. Data are a mean +/-SEM of three independent experiments. Statistical significance was analysed using 
t-test.
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anti-Ubiquitin, anti-ERK2, anti-pERK1/2, anti-Akt and 
anti-pAkt provided by Santa Cruz. Anti-PHLPPL (Bethyl), 
anti-p21 (Calbiochem), anti-p4EBP1, anti-4EBP1 (Cell 
Signalling) and anti-pS213 AR (Abcam). Plasmids 
used were pARE3-Luc, pCMV-b-gal, pFlag-His-AR 
[35]. pFlag-His-AR and its S213A, S791A and double 
S213A;S791A mutants were generated in house by in vitro 
mutagenesis (Quickchange, Stratagene), pFlag-Usp12 wild 
type and C48A mutant [13], pHA-Ubiquitin and pHA-
Flag-WDR20 and pFlag-Uaf-1 [36]; [28] which were kind 
gifts from Professor Alan D’Andrea (Dana-Farber Cancer 
Institute, Boston), pHA-PHLPP [37] and pHA-PHLPPL 
[21] purchased from Addgene. For the assessment of Akt 
inhibition with and without Usp12 silencing we used Akt 
inhibitors MK-2206 dihydrochloride and Perifosine from 
Addooq Bioscience and PI3K inhibitor GDC-0941 from 
Selleckchem.
Cell culture, transfections and reporter assays
LNCaP, HEK293T, PC3 and COS-7 cells were 
obtained from American Type Culture Collection 
(Manassas, USA). Cells were cultured in RPMI 1640 
media with 2 mM L-glutamine (Invitrogen) supplemented 
with 10% (v/v) foetal calf serum (FCS) at 37°C in 
5% CO2. LNCaP-AI variant cell line was derived in-house 
by culturing LNCaP cells in steroid-depleted media to 
allow for the development of androgen independence [38]. 
Transfections were performed using TransIT-LT1 reagent 
(Mirus Bio) following the manufacturer’s instructions.
For luciferase assays, cells were transfected with 
50 ng pARE3-luc, 10 ng pCMV-b-gal and 10 ng of pFlag-
His-AR, pFlag-Usp12 and pFlag-Uaf-1 as indicated. 
All reactions were balanced with pCMV empty vector. 
Cells were cultured under steroid depleted conditions 
for 72h followed by supplementation with 10nM 
dihydrotestosterone (DHT) for additional 24h. Cells were 
lysed and incubated in 1x Promega luciferase assay reagent 
according to the manufacturer’s instruction and luciferase 
counts per second were established and normalised to 
b-galactosidase activity. Results were normalised to AR 
expression alone in steroid depleted conditions.
siRNA gene silencing and gene expression 
analysis
Usp12 targeting siRNA sequence was 
CAGAUCUCUUCCAUAGCAU[dTdT], WDR20 was 
silenced with siRNA CGAGAAAGAUCACAA 
GCGA[dTdT] and Uaf-1 with CAAAUUGGUUC 
UCAGUAGA[dTdT]. Routinely, we achieved >60%, 
>65% and >80% knockdown for Uaf-1, WDR20 and 
Usp12, respectively in qPCR validation (data not shown). 
LNCaP, LNCaP-AI and PC3 cells were reverse transfected 
with siRNA using RNAiMax (Invitrogen) according to 
manufacturer’s instructions and incubated in culture media 
for 96h prior to cell lysis and analysis by Western blotting 
as described previously [13].
Proliferation analysis
For proliferation analysis, cells were transfected 
with siRNA and treated either with DMSO (controls) 
or with PI3K inhibitor GDC-0941 (0.5µM) or Akt 
inhibitors MK-2206 (1µM) or Perifosine (5µM). IncuCyte 
measurements of cellular occupation of the wells were 
taken every 4 hours and additionally in a separate set of 
experiments cell numbers were counted at 96h to assess 
cellular proliferation.
Immunoprecipitations 
Cells were seeded at 5x105 cells per 90 mm dish 
and transfected with 1µg of each plasmid as indicated, 
incubated for 72h and lysed directly into lysis buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 0.2 mM Na
3
VO4, 
1% NP-40, 1 mM PMSF, 1 mM DTT and 1x protease 
inhibitors (Roche)). Lysates were incubated with 1 µg 
of antibodies as indicated for 16h at 4°C, antibodies 
were pulled down using Protein G Sepharose beads. For 
denaturing IPs, cells were subjected to 20 µM of MG-
132 proteosomal inhibitor treatment for the final 16h 
followed by collection into lysis buffer with an addition 
of 2% SDS and denatured at 100°C for 10 minutes [13]. 
Following denaturation, samples were diluted 10x in 
lysis buffer without SDS and processed as in native IP. 
Immunoprecipitates were analysed using Western blotting.
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